Drug Trial Radar · NCT02070380
Crossover Comparison of MultiHance and Dotarem
Last checked: Nov 20, 2026Latest source record: Jan 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Feb 2014
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.
Conditions
- Brain Disease
Interventions
MultiHance 0.1 mmol/kgDrug
MultiHance administered at 0.1 mmol/kg
DotaremDrug
Dotarem administered at 0.1 mmol/kg
MultiHance 0.05 mmol/kgDrug
MultiHance administered at 0.05 mmol/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global Diagnostic Preference Between the Two ExamsTime frame: Comparison of image sets obtained within 2 to 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samaritan Health Services
Corvallis, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.